Under the terms of its licensing deal, Pharmacia (PHA ) must return the $902 million-selling sleep aid Ambien to its developer, Sanofi-Synthélabo, this spring. That leaves a big sales hole.
Growth for the company's flagship $3.1 billion arthritis drug Celebrex slowed in 2001 after questions were raised about possible cardiovascular side effects.
Last year, the Food & Drug Administration delayed approval of injectable painkiller parecoxib and glaucoma treatment Xalcom pending more data.
Monsanto's (MON ) agribusiness unit has been hurt by resistance to genetically modified seeds. Pharmacia will spin off its remaining stake in the business this fall.